Pressure BioSciences (OTCQB: PBIO) was recently covered in a
Zacks Research Report issued on July 26, 2018, which forecasted PBIO to grow at
a compound annual growth rate (CAGR) of 76 percent in the next five fiscal
years from 2018 to 2022 (http://ibn.fm/DuQR3).
A recent article discussing the report reads: “In the Zacks Small-Cap Research
Report, the company’s fair value for PBIO shares is raised to $12/share from a
previous $10/share. Zacks’ optimism regarding Pressure BioSciences is tied to a
number of recent achievements and collaborative research programs, expansion of
the company’s sales and marketing capabilities and a newly established
multinational co-marketing partner, ISS Inc.”
To view the full article, visit http://ibn.fm/MfjIG
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of our pressure-based technologies in the following areas: (1) the use of our
recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the
biologics contract research services sector, and (2) the use of our
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality,
homogenized, extended shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
